Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION): A Phase II Multi-center Study to Evaluate the Safety and Tolerability of Anakinra, an IL-1 Receptor Antagonist, for Patients Treated With Maintenance Hemodialysis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Anakinra (Primary)
- Indications Renal failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACTION
- 06 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
- 25 May 2017 Planned initiation date changed from 1 May 2017 to 1 Jun 2017.
- 09 May 2017 New trial record